Search the Newsreel

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics Inc. announced that Cincinnati Children's has been activated as the seventh Qualified Treatment Center (QTC) for ZEVASKYN® (prademagene zamikeracel). ZEVASKYN is an autologous gene-modified cellular sheet for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). This activation aims to expand …

Cincinnati Children’s activated for rare wound gene therapy

Abeona Therapeutics announced that Cincinnati Children's has become the seventh Qualified Treatment Center for its rare wound gene therapy, ZEVASKYN, aimed at patients with recessive dystrophic epidermolysis bullosa (RDEB). This activation expands access to the treatment for adult and pediatric RDEB patients in the …

Abeona Therapeutics (NASDAQ:ABEO) Downgraded to Strong Sell Rating by Wall Street Zen

ABEO SA: Prévisions et Estimations des Analystes | ABEO